E2F1: a potential therapeutic target for systematic lupus erythematosus.
E2F1 is a transcriptional activator, which binds to DNA, and regulates the expression of genes involved in the cell cycle progression. Many elegant studies have revealed that E2F1 plays a crucial role in regulating the apoptosis process of DC and T cells. In addition, the pathogenesis of SLE involves marked immune dysfunction, and in particular, the function of immunosuppressive elements of the immune system is impaired, including regulatory T cell function and DC. Thus, therapeutic agents targeting E2F1 might result in important innovative therapies for SLE.